-
1 Comment
Austar Lifesciences Limited is currently in a long term uptrend where the price is trading 188.1% above its 200 day moving average.
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.3.
Austar Lifesciences Limited's total revenue sank by 9.3% to $518M since the same quarter in the previous year.
Its net income has increased by 225.9% to $13M since the same quarter in the previous year.
Finally, its free cash flow grew by 43.8% to $18M since the same quarter in the previous year.
Based on the above factors, Austar Lifesciences Limited gets an overall score of 4/5.
Industry | Medical Devices |
---|---|
Sector | Healthcare |
Exchange | HK |
CurrencyCode | HKD |
ISIN | KYG0632L1023 |
Market Cap | 431M |
---|---|
Beta | 1.51 |
Target Price | None |
PE Ratio | 28.0 |
Dividend Yield | None |
Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. The company operates through Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It also offers clean utility and bioprocess equipment, clean room, automation control and monitor system; bioprocess equipment consumables, and laboratory solutions. In addition, the company provides pharmaceutical process contamination control; packaging and aseptic containment; biosafety lab animal equipment, and consumables, as well as offers powder and solid equipment; freeze-dryer, sterile filling and visual inspection equipment. Further, it offers project management and process engineering; engineering design and consulting services; operation and maintenance of facility management systems. Additionally, the company provides lifecycle digital solutions and professional consulting services. Austar Lifesciences Limited was founded in 1991 and is headquartered in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 6118.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025